Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis

Journal of Clinical Rheumatology

Volumn 12, Issue 2, 2006, Pages 83-86

  Mirkinson, Laura J ^a,b   Nagle, David ^a   Jones, Olcay Y ^a   Kadom, Nadja ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Anakinra; Human herpesvirus 6 (HHV 6); Interleukin 1 (IL 1); Systemic onset juvenile idiopathic rheumatoid arthritis (SoJIA)

Indexed keywords

ETANERCEPT; GANCICLOVIR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VIRUS DNA;

ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; BRAIN BIOPSY; CASE REPORT; CEREBELLUM DISEASE; CEREBROSPINAL FLUID; DRUG ERUPTION; DRUG FEVER; DRUG TREATMENT FAILURE; ENCEPHALITIS; FEVER; HOSPITAL READMISSION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN TISSUE; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; MALE; MENTAL HEALTH; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD, PRESCHOOL; ENCEPHALITIS, VIRAL; FEVER; GANCICLOVIR; HERPESVIRUS 6, HUMAN; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RECEPTORS, INTERLEUKIN-1; ROSEOLOVIRUS INFECTIONS; SIALOGLYCOPROTEINS;

EID: 33748174516     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000208650.99508.4e     Document Type: Article

References (30)

1. Lopreiato JO, Katona IM. Parvovirus B19-induced chronic arthropathy in a child. Clin Pediatr (Phila). 1993;32:305-307.
2. Wada Y, Kobayashi M, Kubo M. A girl with systemic onset juvenile rheumatoid arthritis suspected to be due to human parvovirus B19 infection. Kansenshogaku Zasshi. 1997;71:468-473.
3. Heaton DC, Moller PW. Still's disease associated with Coxsackie infection and haemophagocytic syndrome. Ann Rheum Dis. 1985;44:341-344.
4. Cimmino MA, Trevisan G. Lyme arthritis presenting as adult onset Still's disease. Clin Exp Rheumatol. 1989;7:305-308.
5. Tsukahara M, Tsuneoka H, Tateishi H, et al. Bartonella infections associated with systemic juvenile rheumatoid arthritis. Clin Infect Dis. 2001;32:e22-e23.
6. Ward SC, Wiselka MJ, Nicholson KG. Still's disease and myocarditis associated with recent mumps infection. Postgrad Med J. 1988;64:693-695.
7. Clark D. Human herpesvirus type 6 and multiple sclerosis. Herpes. 2004;11(suppl 2):112A-119A.
8. Durno C, Jones N, Hebert D, et al. Evidence linking human herpesvirus-6 (HHV-6) with disease in gastrointestinal transplantation. Transplant Proc. 2000;32:1235-1237.
9. Kato Z, Kozawa R, Teramoto T, Hashimoto K, Shinoda S, Kondo N. Acute cerebellitis in primary human herpesvirus-6 infection. Eur J Pediatr. 2003;162:801-803.
10. Daibata M, Taguchi H. Human herpesvirus 6 and adult-onset Still's disease. Am J Med. 2002;113:532.
11. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis. 2000;59(suppl I):i103-i108.
12. Zhang PA, Li Y, Xu P, Wu JM. Polymorphisms of interleukin-1B and interleukin-1 receptor antagonist genes in patients with chronic hepatitis B. World J Gastroenterol. 2004;10:1826-1829.
13. Muller K, Herner EB, Stagg A, et al. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheum. 1998;37:562-569.
14. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis. Arthritis Rheum. 1995;38:211-220.
15. Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol. 2003;15:581-586.
16. DeBenedetti F, Massa M, Pignatti P, et al. Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J Rheumatol. 1995;22:1581-1585.
17. Raziuddin S, Bahabri S, Al-Dalaan A, et al. A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin Immunol Imunopathol. 1998;86:192-198.
18. DeBenedetti F, Pignatti P, Bernasconi S, et al. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. J Rheum. 1999;26:425-431.
19. Yilmaz M, Kendirli SG, Altintas D, et al. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol. 2001;20:30-35.
20. Maeno N, Take S, Imanaka H, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004;50:1935-1938.
21. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005;52:1960-1967.
22. Kineret (anakinra). Available at: www.kineretrx.com. Amgen, Inc; 2004.
23. Fitzgerald AA, LeClercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794-1803.
24. Godinho F, Jose Santos M, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis. Published online first Sept 16, 2004.
25. Carrasco R, Smith JA, Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs. 2004;6:137-146.
26. Daily NJ, Aksentijevich I, Chae JJ, et al. Interleukin-1 receptor antagonist anakinra in the treatment of neonatal onset multisystem inflammatory disease. Arthritis Rheum. 2004;50(suppl):S440.
27. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheum. 2004;31:2071-2075.
28. Irigoyen PI, Olson J, Hom C, et al. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum. 2004;50(suppl):S437.
29. Henrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum. 2004;50(suppl):S438.
30. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-1486.